Skip to main content
  • Enanta Pharmaceuticals rang the bell at NASDAQ

    July 26, 2013

enantaDr. Helmut M. Schuehsler, Chairman of TVM Capital Group’s Healthcare and Life Science Practice, participated in opening the NASDAQ trading session on Friday, July 26 2013 at 9.30 am in New York City, along with Enanta’s CEO, Jay Luly, and other members of the management and the board of directors from Enanta Pharmaceuticals Inc. This follows the recent successful Initial Public Offering of Enanta Pharmaceuticals Inc. (NASDAQ:ENTA), a portfolio firm of the TVM Capital Life Science Ventures practice, earlier this year. The bell ringing ceremony is also to raise awareness for the 6th World Hepatitis Day, working in partnership with the World Health Organisation (WHO)

For photos, videos and information on the bell ringing session please visit:

Following the Enanta IPO, a second TVM Capital Life Science portfolio firm, gene therapy company bluebird bio Inc. (NASDAQ:BLUE) raised $101 million in an IPO through the sale of a bumped-up number of shares above its proposed price range in June. TVM Capital invested in the company more than 7 years ago, when gene therapy was still out of favor with investors, and helped the company reposition itself, stage a restart and over the years raise substantial capital in several rounds of financings, and add excellent new investors. The company holds tremendous promise to deliver curative gene therapies for major diseases.

TVM Capital Group is an affiliation of globally acting private equity and venture capital firms with an operating track record of close to 30 years. Its investment teams have financed more than 250 emerging companies in across several industries since 1984. The life sciences and healthcare activities of the firm were started in 1990, and boast more than 120 investments and almost 90 exits in the last 23 years, including more than 40 initial  public offerings on all major U.S. and European stock exchanges. TVM Capital Group members are focusing on some of the most attractive and high-growth verticals in the broader healthcare markets, financing innovative products  and technologies in the European and U.S. biopharmaceutical and medical device markets, as well as healthcare services in the Middle East and India.

TVM Capital Group funds operate globally with dedicated Life Science venture capital funds advised by group members TVM Life Science Management in Montreal and TVM Capital in Munich, and its healthcare private equity fund managed by TVM Capital MENA out of Dubai.